antiplatelets

MOA: inhibition of COX-1 which inhibits TXA₂ (very slight inhibition of COX-2 170:1 ratio)

• Indications:
• 1^o ppx of coronary events (recently questioned)
• 2^o ppx in pts with hx of acute MI, post MI, & UA
• Post CABG surgery
• Pre and post tx of coronary angioplasty/stent (PCI)
• Combo tx with plavix for UA and post PCI/stent procedure
• Ppx for stroke d/t cardioembolic embolism 2^o to a. fib
• Ppx of non-cardioembolic (lacunar) stroke, TIAs, peripheral vascular disease

MOA: Irreversibly inhibits the binding of ADP to its receptors (P2Y₁₂ and P2Y₁) on the platelets which inhibits transformation of GPIIb/IIIa receptor into its active form

• Indications: 
• Post ACS (UA/NSTEMI), post PCI/stent
• Combo tx with asa for PCI/stent
• Ppx of stroke/TIA in patients unable to take ASA

MOA: Prodrug with two pathways. Irreversible binding to platelets which inhibits ADP binding to platelet receptors (P2Y12)

• Indications:
• Alternative to ASA if ASA is CI
• Ppx in high-risk pts with arterial thromboembolism
• Stroke ppx in patients with noncardio-embolic TIA or stroke
• Cardio-embolic stroke prevention (with ASA) d/t a. fib when oral anticagulants cannot be taken
• ACS (UA/NSTEMI/STEMI)
• Combo tx with ASA post PCI/stent placement